Abbott Diagnostics has introduced the mView performance monitoring subscription for its m2000 molecular diagnostics system. The web-based dashboard offers configurable reports to automate data analysis and measure laboratory efficiency.
A new study in the journal Cancer finds that Myriad’s myRisk hereditary cancer test identifies 43% more patients with breast cancer risk.
The companies’ partners will take aim at transforming pathology workflow, addressing industry challenges related to case reporting, integration of molecular and genetic technologies, and synoptic reporting.
A study presented at ICAAC 2014 finds that the clinical testing volume and positivity rate of the chikungunya virus both grew after the first case spread to the Western Hemisphere this year.
A new agreement with Premier enables Meridian to offer member facilities its Illumigene molecular diagnostic tests and instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, B. pertussis, and M. pneumonia.
BluePrint proves superior to conventional subtyping for analyzing breast cancer before surgery, says a paper in the Annals of Surgical Oncology.
A preliminary study suggests that metastatic prostate cancer patients with detectable levels of AR-V7 in their blood should avoid two widely used drugs.
An international multispecialty team offers guidance on eligibility for active surveillance, providing low-risk prostate cancer patients a less-harmful treatment option.
Poster presentations at the 2014 Interscience Conference on Antimicrobial Agents and Chemotherapy will examine Verigene testing paired with active antimicrobial stewardship programs.
The 2014 AMP annual meeting will be a premier gathering of molecular pathology experts and professionals aimed to celebrate the progress made in genomic medicine over the past two decades.